Align Technology, IncNasdaq: ALGN
Health Care · Health Care Supplies
$182.23
+5.01%
Vol: 774K
Research Digest
Friday, June 19, 2026
Align Technology announces $200M share buyback alongside Q1 2026 revenue of $1.04B beating estimates by 1.8%, though stock faces scrutiny near $170 amid rising expenses and modest revenue growth outlook of 3-4% for full year.
Align Technology (ALGN) reported Q1 2026 revenue of $1,040.1 million, up 6.2% year-over-year and beating estimates by 1.8%, with non-GAAP diluted EPS of $2.58 versus the $2.30 estimate. The company simultaneously announced a $200 million share repurchase program and reaffirmed full-year fiscal 2026 guidance for worldwide revenue growth of 3%-4% and Clear Aligner volume growth in the mid-single digits. GAAP operating margin guidance is slightly below 18%, representing approximately 400 basis points improvement over 2025. The stock rose 3.5% to $178 on June 9 but has since retreated toward $170 amid analyst scrutiny over rising expenses and modest top-line growth trajectory. Analyst consensus price target stands at $201.69, implying meaningful upside from current levels. Align was recognized for the fifth consecutive year as a Top 100 Global Innovator.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Align Technology shares rose 5.3% to $163.42 on May 20 after the annual meeting reelected all ten directors and approved executive compensation.Positive▶
At the May 20, 2026 annual meeting, Align Technology shareholders elected all ten director nominees with support of 56.7-59.0M shares each and approved the advisory executive pay plan. Shares climbed 5.3% on the day to $163.42. Earlier in May, the company announced a $200M tranche of buybacks under its $1B repurchase program, running May to October 2026 via a Rule 10b5-1 plan. Q1 2026 results showed record Invisalign shipments of 685.7K units (+6.7% YoY) and revenue of $1.04B (+6.2% YoY). Align was also named a Top 100 Global Innovator in the 2026 LexisNexis Innovation Momentum report for the fifth consecutive year. Analyst consensus is Buy with average price target of $209.07 from 16 analysts.
May 20Align Technology announced a new $1 billion share repurchase program after solid Q1 2026 results and AAO product showcase.Positive▶
Align Technology's board authorized a new $1 billion stock repurchase program over three years, with an immediate $200 million Rule 10b5-1 open-market repurchase from May through October 2026. Q1 2026 revenue rose 6.2% YoY to $1.04 billion, beating guidance midpoint by 2%, with adjusted EPS of $2.58 and Clear Aligner revenue up 7.4% to $856M on 6.7% volume growth. Gross margin improved to 70.8%. The company showcased its Invisalign Specifix 3D Printed Attachment System and updated Palatal Expander at the AAO Annual Session May 1-3 in Orlando. Q2 guidance calls for 4% revenue growth. Consensus rating is Buy with median PT of $175.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18Evercore ISI raised Align Technology price target to $220 from $200 following Q1 margin resilience and a new $1 billion share buyback authorization.Positive▶
Evercore ISI raised its Align Technology price target to $220 from $200 in mid-May 2026 citing margin resilience, while Mizuho Securities reiterated a Buy rating and UBS maintained Hold. The Board authorized a new $1.0 billion stock repurchase program over the next three years, on top of a $200 million plan announced in early May. Q1 2026 revenue grew 6.2% to $1.04 billion with EPS of $1.57, driven by Clear Aligner revenue up 7.4% to $856 million on 6.7% case-shipment growth, with strength in Europe, Asia Pacific and Latin America. Management reaffirmed fiscal 2026 guidance with Q2 revenue growth of approximately 4%. Align was also recognized as a Top 100 Global Innovator for the fifth straight year.
May 15Align Technology Q1 2026 revenue up 6.2% to $1.04B with $200M buyback launched May 1 and FY26 guidance reaffirmed.Positive▶
Align Technology reported Q1 2026 revenue of $1.040 billion, up 6.2% year-over-year and 2% above guidance midpoint. Adjusted EPS came in at $2.58, beating FactSet consensus. Clear Aligner revenue rose 7.4% YoY to $856 million driven by double-digit volume growth in Europe, APAC, and Latin America. North America remained stable but lagged. The company launched a $200 million open market stock repurchase on May 1, 2026, to be completed by October 2026. Q2 guidance includes 4% revenue growth driven by sequential aligner growth and flat prices. The stock trades at a premium 29.3x P/E with a recent $153.5M one-off loss limiting room for missteps.
May 14Align Technology beats Q1 2026 estimates with EPS $2.58 and announces $200M buybackPositive▶
Align Technology reported stronger-than-expected Q1 2026 results on May 13, 2026, with EPS of $2.58 beating forecasts of $2.26 and revenue of $1.04B up 6.2% YoY. Clear Aligner revenue grew 7.4% to $856M as case shipments increased 6.7% to 685.7K. Gross margin improved to 70.8% despite $30.6M of legal settlement expense. The company announced a $200M share repurchase program and reaffirmed fiscal 2026 guidance. ALGN stock traded between $160.88-$165.77 on May 13, with analyst consensus price target of $201.69 indicating significant upside potential. The Q1 beat and capital return should support sentiment, though investors remain focused on macroeconomic pressure on consumer dental spend.
May 13No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| WSTWEST | $328.37 | +1.48% | +7.3% | 34.3x | 1.18 | $23.2B |
| ALGNALIGN | $182.23 | +5.01% | +11.4% | 14.7x | 1.67 | $13.0B |
| COOCOOPER | $65.96 | +1.39% | +6.7% | 13.2x | 0.87 | $12.9B |
| LLYELI | $1,099.89 | -1.09% | +7.8% | 24.7x | 0.52 | $979.6B |
| JNJJOHNSON | $228.45 | -2.46% | -0.4% | 18.0x | 0.26 | $549.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.